Canadian Manufacturing

Adastra’s application for controlled substances dealer’s license under review

The Company expects that having the ability to do extraction research and development into psychedelic compounds will prepare it to collaborate with partners.

September 1, 2021  by CM Staff

Known for its renowned cannabis concentrate products, Adastra has now successfully taken the first steps to become a licensed cultivator, tester, extractor, and seller of controlled substances, including Psilocybin, Psilocin, MDMA, N, N-Dimethyltryptamine (DMT), 5-MeO-DMT, and LSD. (CNW Group/Adastra Holdings Ltd.)

LANGLEY — Adastra Holdings Ltd., a company involved in ethnobotanical and cannabis science products, announced that its wholly owned subsidiary Adastra Labs Inc. has received acceptance of its application for a Controlled Drugs and Substances Dealer’s License by Health Canada. Health Canada is now formally reviewing the application.

A Dealer’s License would permit Adastra to perform the following activities:

  • Procure controlled substances, including by import, synthesis, propagation, cultivation, and harvesting of psychedelic mushrooms for Psilocybin extraction;
  • Research and manufacture controlled substances such as Psilocybin and Psilocin;
  • Business-to-business sale of controlled substances, including by export; and
  • Sale of controlled substances via pharmacies.

Known for its renowned cannabis concentrate products, Adastra has now successfully taken the first steps to become a licensed cultivator, tester, extractor, and seller of controlled substances, including Psilocybin, Psilocin, MDMA, N, N-Dimethyltryptamine (DMT), 5-MeO-DMT, and LSD . When the Dealer’s license is formally approved, Adastra Labs expects to conduct the majority of this work out of its 13,500 square foot production facility located in Langley, BC.

“Adastra Labs’ laboratory is perfectly positioned to conduct groundbreaking research into psychedelic formulations and testing due to the existing GMP-compliant construction, security and our proven track record operating in the cannabis sector,” said Donald Dinsmore, COO, Corporate Secretary and a director of the Company. “With this infrastructure in place, securing a Controlled Drugs and Substances Dealer’s License a logical next step for the Company. Putting quality first throughout, our processes will allow us to serve the emerging medical market for these substances.”

Advertisement

The Company expects that having the ability to do extraction research and development into psychedelic compounds will prepare it to collaborate with partners such as medical doctors, pharmaceutical companies, and pharmacies as clinical trials lead to the legalization of psychedelics and the advancement of micro-dosing in the near future.

“Ongoing research into compounds like Psilocybin has demonstrated that there may be significant positive impacts when psychedelics are used to treat mental health issues such as PTSD, anxiety, depression, and even migraines,” said Michael Forbes, CEO and a director of Adastra. “With our team’s extensive background in plant biochemistry, pharmacology, and chemistry, as well as clear indications of changing societal and regulatory environments regarding psychedelic treatments for mental health issues, it is clear that Adastra is well-suited to enter into the psychedelic space.”


Print this page

Related Stories